All Releases
 |
Manhattan Pharmaceuticals to Present At the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
Nov 2, 2007
|
7.7 KB |
|
| |
NEW YORK, Nov 2, 2007 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced that Douglas Abel, president and chief executive officer, will present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on Monday, November 5, 2007 at 2:20 PM ET. The conference is being held at The Palac...
|
|
Manhattan Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Topical PTH (1-34) for Psoriasis
Oct 31, 2007
|
10.3 KB |
|
| |
NEW YORK, Oct 31, 2007 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced that the first patient has received the initial dose in their Phase 2a clinical study of the company's lead product candidate, topical PTH (1-34) for the treatment of psoriasis. This U.S. multi-center, randomized, double-blin...
|
|
Manhattan Pharmaceuticals to Present At Friedland Winter Life Sciences Conference
Oct 30, 2007
|
7.7 KB |
|
| |
NEW YORK, Oct 30, 2007 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced that Douglas Abel, president and chief executive officer, will present at the Friedland Winter Life Sciences Conference on Thursday, November 1, 2007 at 9:59 AM ET. The conference is being held at the Double Tree Guest Suites...
|
|
Manhattan Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
Oct 18, 2007
|
7.6 KB |
|
| |
NEW YORK, Oct 18, 2007 (BUSINESS WIRE) -- Manhattan Pharmaceuticals, Inc. (AMEX: MHA) today announced that Douglas Abel, president and chief executive officer, will present at the Paramount BioSciences Healthcare Conference on Tuesday, October 23, 2007 at 3:15 PM ET. The conference is being held at the Waldorf Astoria Hotel in New York City.
Re...
|
|
Manhattan Pharmaceuticals to Present at BIO Investor Forum 2007
Oct 8, 2007
|
7.4 KB |
|
| |
NEW YORK, Oct 08, 2007 (BUSINESS WIRE) -- Manhattan Pharmaceuticals, Inc. (AMEX: MHA) today announced that Douglas Abel, president and chief executive officer, will present at the BIO Investor Forum 2007 on Wednesday, October 10, 2007 at 6:45PM ET (3:45PM PT). The conference is being held at The Palace Hotel in San Francisco.
To access the audi...
|
|
Manhattan Pharmaceuticals to Provide a Pipeline Update
Oct 2, 2007
|
7.8 KB |
|
| |
NEW YORK, Oct 02, 2007 (BUSINESS WIRE) -- Manhattan Pharmaceuticals, Inc. (AMEX: MHA) today announced that Douglas Abel, president and chief executive officer, will provide a pipeline update on Wednesday, October 3, 2007 at 4:30 PM ET. This update is being given as part of the company's Stockbroker & Investor Day 2007 being held at The American Sto...
|
|
Manhattan Pharmaceuticals to Present at Friedland Undervalued Equities Conference
Sep 24, 2007
|
7.3 KB |
|
| |
NEW YORK, Sep 24, 2007 (BUSINESS WIRE) -- Manhattan Pharmaceuticals, Inc. (AMEX: MHA) today announced that Douglas Abel, president and chief executive officer, will present at the Friedland Undervalued Equities Conference on Tuesday, September 25, 2007 at 11:34 AM ET. The conference is being held at The Roosevelt Hotel in New York City.
Registr...
|
|
Manhattan Receives Notification from AMEX of Non-compliance with Certain Listing Standards
Sep 21, 2007
|
8.3 KB |
|
| |
NEW YORK, Sep 21, 2007 (BUSINESS WIRE) -- Manhattan Pharmaceuticals, Inc. (AMEX: MHA) received notice from the American Stock Exchange (AMEX) dated September 18, 2007 indicating that the company is not in compliance with Section 1003(a)(ii) of the AMEX Company Guide with stockholder's equity of less than $4,000,000 and losses from continuing operat...
|
|
Manhattan Pharmaceuticals to Present at Wall Street Analyst Forum Biotech & Specialty Pharma Conference
Sep 20, 2007
|
7.4 KB |
|
| |
NEW YORK, Sep 20, 2007 (BUSINESS WIRE) -- Manhattan Pharmaceuticals, Inc. (AMEX: MHA) today announced that Douglas Abel, president and chief executive officer, will present at the Wall Street Analyst Forum Biotech & Specialty Pharma Conference on Thursday, September 20, 2007 at 2:40 PM ET. The conference is being held at The Princeton Club in New Y...
|
|
Webcast Alert: Biotech/Pharma/Healthcare On-line Forum
Sep 17, 2007
|
6.3 KB |
|
| |
NEW YORK, Sep 17, 2007 (BUSINESS WIRE) -- Manhattan Pharmaceuticals (AMEX: MHA) announces the following Webcast:
What: Biotech/Pharma/Healthcare On-line Forum
When: September 18, 2007 @ 12:30 PM Eastern
Where: http://www.investorcalendar.com/ClientPage.asp?ID=120839
How: Live over the Internet -- Simply log on to the web at the addr...
|
|
Manhattan Pharmaceuticals to Present at Informed Investors Biotech/Pharma/Healthcare On-line Forum
Sep 17, 2007
|
7.4 KB |
|
| |
NEW YORK, Sep 17, 2007 (BUSINESS WIRE) -- Manhattan Pharmaceuticals, Inc. (AMEX: MHA) today announced that Douglas Abel, president and chief executive officer, will present at the Informed Investors Biotech/Pharma/Healthcare Online Forum on Tuesday, September 18, 2007 at 12:30 PM ET.
To access the audio webcast for this presentation please go t...
|
|
Manhattan Pharmaceuticals Provides Update on Clinical Pipeline
Jul 10, 2007
|
11.5 KB |
|
| |
NEW YORK, July 10 /PRNewswire-FirstCall/ -- Manhattan Pharmaceuticals, Inc. (Amex: MHA - News) today provided an update regarding the company's pipeline. As announced yesterday, the company intends to continue with the advancement of its four clinical stage product candidates, and the exploration of other opportunities in the areas of dermatology/i...
|
|
Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Jul 9, 2007
|
10.0 KB |
|
| |
NEW YORK, July 9 /PRNewswire-FirstCall/ -- Manhattan Pharmaceuticals, Inc. (Amex: MHA - News) today announced results of the company's two Phase 2a clinical trials of oral Oleoyl-estrone (OE). The results of both randomized, double-blind, placebo-controlled studies, one in common obesity and the other in morbid obesity, demonstrated no statisticall...
|
|
Manhattan Pharmaceuticals Acquires Hedrin ™ for the Treatment of Head Lice
Jun 27, 2007
|
10.7 KB |
|
| |
NEW YORK, JUNE 27 -- Manhattan Pharmaceuticals, Inc. (Amex: MHA - News) today announced that it has acquired exclusive, North American rights to develop and commercialize Hedrin™, a novel, non-insecticide product candidate for the treatment of head lice. Hedrin is currently marketed in Europe ...
|
|
Manhattan Pharmaceuticals to Webcast Annual Shareholder Meeting
May 22, 2007
|
5.6 KB |
|
| |
NEW YORK, May 22, 2007 -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA - News) today announced it will host a live webcast of its annual shareholder meeting scheduled for Thursday, May 24, 2007 at 10:30 a.m. EDT. In addition to voting on the items in the Proxy Statement the meeting will also include a presentation by Douglas Abel, president and chief ...
|
|
Manhattan Pharmaceuticals Successfully Completes Dosing Portion of Two Phase 2a Clinical Trials of Oral Oleoyl-estrone for Obesity
May 10, 2007
|
8.7 KB |
|
| |
NEW YORK, NY, MAY 10, 2007 � Manhattan Pharmaceuticals, Inc. (AMEX: MHA) today announced it has successfully completed patient dosing in two separate, ongoing Phase 2a clinical trials of oral Oleoyl-estrone (OE). The first trial is evaluating OE for the treatment of common obesity and the second trial is evaluating OE for treatment of morbid...
|
|
Manhattan Pharmaceuticals to Present At Acumen/BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference
May 9, 2007
|
5.7 KB |
|
| |
NEW YORK, May 9, 2007 - Manhattan Pharmaceuticals, Inc. (AMEX:MHA - News) today announced that Douglas Abel, president and chief executive officer, will present at the Acumen/BioFin Rodman and Renshaw 4th Annual Global Healthcare Conference on Monday, May 14 at 5:50am EDT (11:50am local time). The conference is being held May 14-15, 2007 at the Le ...
|
|
Manhattan Pharmaceuticals Announces License Agreement and Expanded Pipeline
Apr 4, 2007
|
11.3 KB |
|
| |
NEW YORK, NY APRIL 4, 2007 - Manhattan Pharmaceuticals, Inc. (AMEX: MHA) today announced that it has acquired exclusive, North American rights to develop and commercialize two novel product candidates from Thornton & Ross Limited - the largest independent pharmaceutical manufacturer in the United Kingdom (UK). The two acquired product candidates ar...
|
|
Manhattan Pharmaceuticals Completes $8.6 Million Private Placement
Apr 2, 2007
|
6.2 KB |
|
| |
NEW YORK, NY APR 2, 2007 - Manhattan Pharmaceuticals, Inc. (AMEX: MHA) today announced it completed a private placement of common stock and warrants with certain institutional and other accredited investors. The company expects to use the net proceeds for general corporate purposes.The company sold approximately 10.2 million shares of i...
|
|
AMEX Accepts Manhattan Pharmaceuticals' Plan to Regain Compliance with Continued Listing Standards
Mar 27, 2007
|
6.1 KB |
|
| |
NEW YORK, NY MAR 27, 2007 � Manhattan Pharmaceuticals, Inc. (AMEX: MHA) today announced that the American Stock Exchange (AMEX) has accepted the Company's plan to regain compliance with continued listing standards of AMEX. The Company's plan was submitted in response to a letter from AMEX which informed the Company that it was not in complia...
|
|
|
